Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7862]

FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC

FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC

ASH 2022: MajesTEC-2 trial of teclistamab-cqyv in combination with daratumumab and hyaluronidase-fihj and lenalidomide shows clinical activity in RRMM

ASH 2022: MajesTEC-2 trial of teclistamab-cqyv in combination with daratumumab and hyaluronidase-fihj and...

ASH 2022: New results from the phase 3 GLOW study of fixed-duration treatment with ibrutinib plus venetoclax demonstrate robust efficacy and sustained response in older, unfit patients with previously untreated chronic lymphocytic leukaemia

ASH 2022: New results from the phase 3 GLOW study of fixed-duration treatment with ibrutinib plus venetoclax...

ASH 2022: Novel drug shows early promise in treating multiple myeloma

ASH 2022: Novel drug shows early promise in treating multiple myeloma

ASH 2022: Efficacy and subgroup analyses from MAIA study showing long-term results of daratumumab based regimen in newly diagnosed, transplant-ineligible MM

ASH 2022: Efficacy and subgroup analyses from MAIA study showing long-term results of daratumumab based regimen in...

ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma

ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma

SABCS 2022: Camizestrant may be superior to fulvestrant in hormone receptor-positive, HER2-negative breast cancer

SABCS 2022: Camizestrant may be superior to fulvestrant in hormone receptor-positive, HER2-negative breast cancer

New technology for inhibiting T cell exhaustion and reinvigorating exhausted T cells, which is essential for immune cell therapy of solid cancer

New technology for inhibiting T cell exhaustion and reinvigorating exhausted T cells, which is essential for...

$FDA approves olutasidenib for relapsed or refractory acute myeloid leukaemia with a susceptible IDH1 mutation$

FDA approves olutasidenib for relapsed or refractory acute myeloid leukaemia with a susceptible IDH1 mutation

P53 could be key to therapies for salivary gland cancer

P53 could be key to therapies for salivary gland cancer

More from ecancer